Mr. Patrick Montpetit is Chief Financial Officer, Vice President of Immunotec Inc. Prior to joining the Company, Mr. Montpetit held a number of senior financial management positions, most recently as VicePresident, Finance and Chief Financial Officer of Bioniche Life Sciences Inc . His experience over the past fifteen years was in the life sciences and biopharmaceutical industries where he was involved in raising over 250 million dollars in growth capital. During this time, he served as Chairman of the Quebec Biotechnology Association and as a director of the Montreal InVivo organization. Prior to Bioniche, Mr. Montpetit was the Director of Finance, Administration, Commercial Agreements and Alliances with DSM Biologics Inc., a multinational pharmaceutical company and the Netherlands. Mr. Montpetit is a Chartered Accountant combined with a specialty in corporate finance from the Canadian Institute of Chartered Accountants.
CFO, Vice President
President Since 2009
The company has return on total asset (ROA) of 4.83 % which means that it generated profit of $4.83 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 5.35 % meaning that it generated $5.35 on every $100 dollars invested by stockholders.
The company has accumulated 2.05 M in total debt with debt to equity ratio (D/E) of 0.17 which may suggest the company is not taking enough advantage from borrowing. Immunotec Inc has Current Ratio of 1.39 which is within standard range for the sector.
Entity SummaryImmunotec Inc., a network marketing company, manufactures and sells natural health solutions and dietary supplements in Canada, the United States, Europe, Mexico, and the Caribbean. Immunotec Inc [IMM] is traded on TSX Venture Exchange in Canada. It is located in VaudreuilDorion, QC JV V and employs 13 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| IMM TSXV #B1P77Y5CA
Currency: CAD - Canadian Dollar
Traded on TSX Venture Exchange
Immunotec Inc has less than 16.16 (%) percent chance of experiencing financial distress in the next 2 years of operations.
Immunotec price boundaries
Promote Immunotec and Patrick Montpetit